<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01511718</url>
  </required_header>
  <id_info>
    <org_study_id>3874/06-07</org_study_id>
    <nct_id>NCT01511718</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study for Ondansetron Hydrochloride Tablets 8 mg Under Fed Condition</brief_title>
  <official_title>Open Label, Balanced, Randomized, Two-treatment, Two-period, Two Sequence, Single Dose, Crossover, Oral Bioequivalence Study of Ondansetron Hydrochloride Tablets 8 mg With Zofran® (Containing Ondansetron Hydrochloride Dihydrate) Tablets 8 mg in Healthy, Adult, Human Subjects Under Fed Condition.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, balanced, randomized, two-treatment, two-period, two sequence,single
      dose, crossover, oral bioequivalence study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was an open label, balanced, randomized, two-treatment, two-period, two
      sequence,single dose, crossover, oral bioequivalence study of Ondansetron Hydrochloride
      tablets 8 mg of Dr. Reddy's Laboratories Limited, India comparing with that of Zofran®
      (containing Ondansetron Hydrochloride Dihydrate) tablets 8 mg of GlaxoSmithKline, USA in
      healthy, adult, human subjects under fed condition. 26 subjects are enrolled in the study,
      and 23 subjects are completed the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area unde curve (AUC)</measure>
    <time_frame>First one was within 1 hour prior to drug administration (0.0) and others at 0.33,0.67,1,1.33, 1.67, 2, 2.5, 3, 3.5,4,6,9,12,15,18 and 24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Ondansetron Hydrochloride Tablets 8 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ondansetron Hydrochloride Tablets 8 mg of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zofran Tablets 8 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zofran Tablets 8 mg of GlaxoSmithKline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron Hydrochloride</intervention_name>
    <description>Ondansetron Hydrochloride Tablets 8 mg</description>
    <arm_group_label>Ondansetron Hydrochloride Tablets 8 mg</arm_group_label>
    <other_name>Ondansetron Hydrochloride 8 mg (Dr. Reddy's Laboratories Limited)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron Hydrochloride</intervention_name>
    <description>Zofran Tablets 8 mg</description>
    <arm_group_label>Zofran Tablets 8 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who provide written informed consent.

          -  Subjects who were healthy adults within 18 and 45 years of age (both inclusive).

          -  Body mass index of ≥ 18 kg/m2 and ≤ 25 kg/m2, with body weight not less than 50 kg.

          -  Subjects who had normal health as determined by medical history and physical
             examination performed within 15 days prior to the dosing of period I.

          -  Had normal ECG, Chest X-ray and vital signs

          -  Availability of subjects for the entire study period and willingness to adhere to
             protocol requirements as evidenced by written informed consent.

          -  If subject is a female volunteer and is of child bearing potential practicing an
             acceptable method of birth control for the duration of the study as judged by the
             investigator(s),such as condoms, foams, jellies, diaphragm, intrauterine device(IUD),
             or abstinence.

        or

          -  is postmenopausal for at least 1 year or

          -  is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or
             hysterectomy has been performed on the subject)

          -  Each female subject were supposed to undergo a urine pregnancy test to check-in for
             period-I, period-II and post study.

        Exclusion Criteria:

          -  Subjects incapable of understanding the informed consent.

          -  Subjects BP ≤ 9060 mm/Hg or BP ≥ 140/90 mm/Hg.

          -  History of hypersensitivity or idiosyncratic reaction to ondansetron or any other
             related drugs.

          -  Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal
             function. Subjects with a history of tuberculosis, epilepsy, asthma(during past 5
             years), diabetes, psychosis or glaucoma were not eligible for the study.

          -  Regular smoker who smokes more than ten cigarettes daily and has difficulty in
             abstaining from smoking for the duration of each study period.

          -  Subjects who has taken over the counter or prescribed medications, including any
             enzyme modifying drugs or any systemic medication with the past 30 days prior to
             dosing in Period-I.

          -  History of any psychiatric illness, which may impair the ability to provide written
             informed consent.

          -  Subjects who have a history of alcohol or substance abuse within the last 5 years.

          -  Subjects with clinically significant abnormal values of laboratory parameters.

          -  Subjects who have participated in any other clinical investigation using experimental
             drug or had bled more than 350 mL in the past 3 months.

          -  Subjects who are unable to or likely to be non-complaint with protocol requirements or
             restrictions.

          -  Any subject in whom ondansetron is contraindicated for medical reasons.

          -  Subjects who are intolerant to venipuncture.

          -  Subjects with positive urine screen for drugs of abuse. All subjects urine samples
             assayed for the presence of drugs of abuse at each study period check-in. Subjects who
             found to have urine concentrations of any of the tested drugs were not allowed to
             participate.

          -  Female volunteers who has used implanted or injected hormonal contraceptives anytime
             during the 6 months prior to study or used hormonal contraceptives with 14 days before
             dosing.

          -  Female volunteers who are not negative in pregnancy test

          -  All female subjects were to be screened for pregnancy at check in of each study
             period. Subjects with positive or inconclusive results were to be withdrawn from the
             study.

          -  Female volunteers who are currently breast feeding.

          -  Female subjects who are pregnant, breast-feeding, or who are likely to become pregnant
             during the study were not to be allowed to participate. Female subjects of child
             bearing potential must either abstain form sexual intercourse or use a reliable
             barrier method (e.g condom, IUD) or contraception during the course of the study
             (first dosing until last blood collection) or they were not to be allowed to
             participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. I.S Gandhi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vimta Labs Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vimta Labs Limited</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500 051</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2012</study_first_submitted>
  <study_first_submitted_qc>January 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2012</study_first_posted>
  <last_update_submitted>January 18, 2012</last_update_submitted>
  <last_update_submitted_qc>January 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Ondansetron</keyword>
  <keyword>crossover</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

